Colonic targeting of aminosalicylates for the treatment of ulcerative colitis

Digestive and Liver Disease

Volumn 37, Issue 6, 2005, Pages 381-388

  Klotz, U ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

Aminosalicylates; Drug targeting; Prodrugs; Ulcerative colitis

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; AMINOSALICYLIC ACID DERIVATIVE; AMPICILLIN; ANTIDIARRHEAL AGENT; ANTIINFLAMMATORY AGENT; BALSALAZIDE; DERSALAZINE; EUDRAGIT; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; MESALAZINE; NCX 456; NITRIC OXIDE MESALAMINE; OLSALAZINE; OMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; SALAZOSULFAPYRIDINE; SULFAPYRIDINE; UNCLASSIFIED DRUG; UR 12746S; URSODEOXYCHOLIC ACID MESALAZINE CONJUGATE; NONSTEROID ANTIINFLAMMATORY AGENT; PRODRUG;

ABDOMINAL PAIN; ADJUVANT THERAPY; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; CLINICAL TRIAL; COLON MUCOSA; CONCENTRATION RESPONSE; DIARRHEA; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG CLEARANCE; DRUG COMPETITION; DRUG DISPOSITION; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOOD DRUG INTERACTION; HEADACHE; HUMAN; MULTIPLE DRUG DOSE; NAUSEA; REMISSION; RESPIRATORY TRACT INFECTION; SHORT SURVEY; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; VOMITING; CHEMICAL STRUCTURE; DRUG DELIVERY SYSTEM; INTESTINE; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGY; RECTAL DRUG ADMINISTRATION; REVIEW;

ADMINISTRATION, ORAL; ADMINISTRATION, RECTAL; AMINOSALICYLIC ACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DRUG DELIVERY SYSTEMS; HUMANS; INTESTINES; MOLECULAR STRUCTURE; PRODRUGS;

EID: 26944479743     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2004.12.011     Document Type: Short Survey

References (77)

1. Svartz N. Salazopyrin-a new sulfanilamide preparation. A. Therapeutic result in rheumatoid arthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestations on treatment with sulfanilamide preparations. Acta Med Scand 110 (1942) 577-590
2. Azad Khan A.K., Piris J., and Truelove S.C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet II (1977) 892-895
3. Van Hees P.A.M., Bakker J.H., and Van Tongeren J.H.M. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut 21 (1980) 632-635
4. Klotz U., Maier K., Fischer C.L., and Heinkel K. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Engl J Med 303 (1980) 1499-1502
5. Das K.M., Eastwood M.A., McManus J.P.A., and Sircus W. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 289 (1973) 491-495
6. Fischer C., and Klotz U. Is plasma level monitoring of sulfasalazine indicated in the treatment of Crohn's disease or ulcerative colitis?. Ther Drug Monit 2 (1980) 153-158
7. Klotz U. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin Pharmacokinet 10 (1985) 285-302
8. Podolsky D. Inflammatory bowel disease. N Engl J Med 347 (2002) 417-429
9. Farrell R., and Peppercorn M.A. Ulcerative colitis. Lancet 359 (2002) 331-340
10. Rizello F., Gionchetti P., Venturi A., Amadini R., Romagnoli R., and Campieri M. Review article: monitoring activity in ulcerative colitis. Aliment Pharmacol Ther 16 Suppl. 4 (2002) 3-6
11. Cohen R.D., Woseth D.M., Thistel R.A., and Hanauer S.B. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 95 (2000) 1263-1276
12. Rizzello F., Gionchetti P., Venturi A., and Campieri M. Review article: medical treatment of severe ulcerative colitis. Aliment Pharmacol Ther 17 Suppl. 2 (2003) 7-10
13. Sandborn W.J. Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis. Am J Gastroenterol 97 (2002) 2939-2941
14. Campieri M. New steroids and new salicylates in inflammatory bowel disease: a critical appraisal. Gut 50 Suppl. III (2002) iii43-iii46
15. Bresci G., Parisi G., Bertoni M., and Capria A. Long-term maintenance treatment in ulcerative colitis: a 10-year follow up study. Dig Liver Dis 34 (2002) 419-423
16. Qasim A., Seery J., and O'Morain C.A. 5-Aminosalicylates in inflammatory bowel disease: choosing the right dose. Dig Liver Dis 323 (2001) 393-398
17. Schwab M., and Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet 40 (2001) 723-751
18. Tursi A., Brandimarte G., Giorgetti G.M., and Nasi G. Assessment of orocaecal transit time in different localization of Crohn's disease and its possible influence on clinical response to therapy. Eur J Gastroenterol Hepatol 15 (2003) 69-74
19. Bruewer M., Stern J., Herrman S., Senninger N., and Herfarth C. Changes in intestinal transit time after proctocolectomy assessed by the lactulose breath test. World J Surg 24 (2000) 119-124
20. Nugent S.G., Kumar D., Rampton D.S., and Evans D.F. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut 48 (2001) 571-577
21. Press A.G., Hauptmann I.A., Hauptmann L., Fuchs B., Fuchs M., and Ewe K. Gastrointestinal pH profiles in patients with inflammatory bowel disease. Aliment Pharmacol Ther 12 (1988) 673-678
22. Fallingborg J. Intraluminal pH of the human gastrointestinal tract. Dan Med Bull 46 (1999) 183-196
23. Frieri G., Pimpo M.T., Andreoli A., Annese V., Comberlato M., Corrao G., et al. Prevention of postoperative recurrence of Crohn's disease requires adequate mucosal concentrations of mesalazine. Aliment Pharmacol Ther 13 (1999) 557-582
24. Frieri G., Giacomelli G., Pimpo M., Palumbo G., Passacantando A., Pantaleoni G., et al. Mucosal 5-aminosalicylic acid concentrations inversely correlate with severity of colonic inflammation in patients with ulcerative colitis. Gut 47 (2000) 410-414
25. Naganuma M., Iwao Y., Ogata H., Inoue N., Funakoshi S., Yamamoto S., et al. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine. Inflamm Bowel Dis 7 (2001) 221-225
26. De Vos M., Verdievel H., Schoonjans R., Praet M., Bogaert M., and Barbier F. Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations. Gut 33 (1992) 1338-1342
27. Klotz U. The role of aminosalicylates at the beginning of the new millennium in the treatment of chronic inflammatory bowel disease. Eur J Clin Pharmacol 56 (2000) 353-362
28. Gisbert J.P., Gomollón F., Maté J., and Pajares J.M. Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease. A systematic review. Dig Dis Sci 47 (2002) 471-488
29. Marshall J.K., and Irvine E.J. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Am J Gastroenterol 95 (2000) 1628-1636
30. Vree T.B., Dammers E., Exler P.S., Sörgel F., Bondesen S., and Maes R.A.A. Liver and gut mucosa acetylation of mesalazine in healthy volunteers. Int J Clin Pharmacol Ther 38 (2000) 514-522
31. Fischer C., Maier K., Stumpf E., von Gaisberg U., and Klotz U. Disposition of 5-aminosalicylic acid, the active metabolite of sulphasalazine, in man. Eur J Clin Pharmacol 25 (1983) 511-515
32. Klotz U., and Harings-Kaim A. Negligible excretion of 5-aminosalicylic acid in breast milk. Lancet 342 (1993) 618-619
33. Goebell H., Klotz U., Nehlsen B., and Layer P. Oroileal transit of slow release 5-aminosalicylic acid. Gut 34 (1993) 669-675
34. Layer P.H., Goebell H., Keller J., Dignass A., and Klotz U. Delivery and fate of oral mesalamine microgranules within the human small intestine. Gastroenterology 108 (1995) 1427-1433
35. Zhou S.Y., Fleisher D., Pao L.H., Li B., Winward B., and Zimmerman E.M. Intestinal metabolism and transport of 5-aminosalicylate. Drug Metab Dispos 27 (1999) 479-485
36. Proudfoot L.E., and Yacyshyn B.R. Mechanisms of transport and structure-permeability relationship of sulfasalazine and its analogs in Caco-2 cell monolayers. Pharm Res 17 (2000) 1168-1174
37. Hein D.W., Doll M.A., Fretland A.J., Leff M.A., Webb S.J., Xiao G.H., et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 9 (2000) 29-42
38. Prakash A., and Spencer C.M. Balsalazide. Drugs 56 (1998) 83-90
39. Muijsers R.B.R., Goa K.L., and Balsalazide. A review of its therapeutic use in mild-to-moderate ulcerative colitis. Drugs 62 (2002) 1689-1705
40. Sandborn W.J., and Hanauer S.B. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther 17 (2003) 29-42
41. Ryde E.M., and Ahnfelt N.O. The pharmacokinetics of olsalazine sodium in healthy volunteers after a single i.v. dose and after oral doses with and without food. Eur J Clin Pharmacol 34 (1988) 481-488
42. Wadworth A.N., Fitton A., and Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease. Drugs 41 (1991) 647-664
43. Järnerot G. Withdrawal rates because of diarrhoea in Dipentum-treated patients with ulcerative colitis are low when Dipentum is taken with food and dose titrated. Gastroenterology 110 (1996) A932
44. Kruis W., Brandes J.W., Schreiber S., Theuer D., Krakamp B., Schütz E., et al. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Aliment Pharmacol 12 (1998) 707-715
45. Courtney M.G., Nunes D.P., Bergin C.F., O'Driscoll M., Trimble V., Keeling P.W.N., et al. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet 339 (1992) 1279-1281
46. Sandberg-Gertzen H., Ryde M., and Jarnerot G. Absorption and excretion of a single 1-g dose of azodisal sodium in subjects with ileostomy. Scand J Gastroenterol 18 (1983) 107-111
47. Ewe K., Becker K., and Ueberschaer B. Systemic uptake of 5-aminosalicylic acid from olsalazine and Eudragit L coated mesalazine in patients with ulcerative colitis in remission. Z Gastroenterol 34 (1996) 225-229
48. Gionchetti P., Campieri M., Venturi A., Rizzello F., Ferretti M., Brignola C., et al. Systemic availability of 5-aminosalicylic acid: comparison of delayed release and an azo-bond preparation. Aliment Pharamcol Ther 10 (1996) 601-605
49. Karamanolis D.G., Papatheodoridis G.V., and Xourgias V. Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine. Eur J Gastroenterol Hepatol 8 (1996) 1083-1088
50. Stretch G.L., Campbell B.J., Dwarakanath A.D., Yaqoob M., Stevenson A., Morris A.I., et al. 5-aminosalicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine. Aliment Pharmacol Ther 10 (1996) 941-947
51. Tzivras M., Konstandinidis A., Hatzis G., Paraskeva M., Skandalis N., and Archimandritis A. Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine. Eur J Gastroenterol Hepatol 9 (1997) 729-730
52. Mahmud N., Weir D.G., and Kelleher D. Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicylic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease. Ir J Med Sci 168 (1999) 228-232
53. Støa-Birketvedt G., and Florholmen J. The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine. Aliment Pharmacol Ther 13 (1999) 357-361
54. Laursen L.S., Stokholm M., Bukhave J., Rask-Madsen J., and Lauritsen K. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut 31 (1990) 1271-1276
55. Frieri G., Pimpo M.T., Palumbo G.C., Onori L., Viscido A., Letella G., et al. Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment. Aliment Pharmacol Ther 13 (1999) 1413-1417
56. Paoluzi P., D'Albasio G., Pera A., Bianchi Porro G., Paoluzi O.A., Pica R., et al. Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one year randomised multicentre trial. Dig Liver Dis 34 (2002) 787-793
57. Forbes A., Cartwright A., Marchant S., McIntyres P., and Newton M. Review article: oral, modified-release mesalazine formulations-proprietary versus generic. Aliment Pharmacol Ther 17 (2003) 1207-1214
58. Prakash A., and Markham A. Oral delayed-release mesalazine. A review of its use in ulcerative colitis and Crohn's disease. Drugs 57 (1999) 383-408
59. Christensen L.A. 5-Aminosalicylic acid containing drugs. Dan Med Bull 47 (2000) 20-41
60. Clemett D., and Markham A. Prolonged-released mesalazine. A review of its therapeutic potential in ulcerative colitis and Crohn's disease. Drugs 59 (2000) 929-956
61. De Vos M. Clinical pharmacokinetics of slow release mesalazine. Clin Pharmacokinet 39 (2000) 85-97
62. Keller J., Goebell H., Klotz U., and Layer P. Release pattern of 5-aminosalicylic acid in human small intestine: importance of galenic preparation. Med Klin 93 (1998) 294-299
63. De Mey C., and Meineke I. Prandial and diurnal effects on the absorption of orally administered enteric coated 5-aminosalicylic acid (5-ASA). Br J Clin Pharmacol 33 (1992) 179-182
64. Wilding I.R., Kenyon C.-J., and Hooper G. Gastrointestinal spread of oral prolonged-release mesalazine microgranules (Pentasa) dosed as either tablets or sachet. Aliment Pharmacol Ther 14 (2000) 163-169
65. Wilding I.R., Behrens C., Tardif S.J., Wray H., Bias P., and Albrecht W. Combined scintigraphic and pharmacokinetic investigation of enteric-coated mesalazine micropellets in healthy subjects. Aliment Pharmacol Ther 17 (2003) 1153-1162
66. Brunner M., Assandri R., Kletter K., Tschurlovits M., Corrado M.E., Villa R., et al. Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. Aliment Pharmacol Ther 17 (2003) 395-402
67. 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers. Aliment Pharmacol Ther 17 (2003) 1163-1169
68. Kruis W., Bar-Meir S., Feher J., Mickisch O., Mritz H., Fazcyk M., et al. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin Gastroenterol Hepatol 1 (2003) 36-43
69. Di Paolo M.C., Paoluzi O.A., Pica R., Iacopini F., Crispino P., Rivera M., et al. Sulphasalazine and 5-aminosalicylic acid in long-term treatment of ulcerative colitis: report on tolerance and side-effects. Dig Liver Dis 33 (2001) 563-569
70. Loftus Jr. E.V., Kane S.V., and Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther 19 (2004) 179-189
71. Van Staa T.P., Travis S., Leutkens H.G.M., and Logan R.F. 5-Aminosalicylic acid and the risk of renal disease: a large British epidemiologic study. Gastroenterology 126 (2004) 1733-1739
72. Hanauer S.B. Review article: aminosalicylate in inflammatory bowel disease. Aliment Pharmacol Ther 20 Suppl. 14 (2004) 60-65
73. Wallace J.L. Nitric oxide-releasing mesalamine: potential utility for treatment of inflammatory bowel disease. Dig Liver Dis 35 Suppl. 2 (2003) S-35-S-40
74. Gálvez J., Garrido M., Rodriguez-Cabezas M.E., Ramis I., de Medina F.S., Merlos M., et al. The intestinal anti-inflammatory activity of UR-12746S on reactivated experimental colitis is mediated through downregulation of cytokine production. Inflamm Bowel Dis 9 (2003) 363-371
75. Mutlu E.A., Farhadi A., and Keshavarazian A. New developments in the treatment of inflammatory bowel disease. Expert Opin Investig Drugs 11 (2002) 365-385
76. Reddy S.M., Sinha V.R., and Reddy D.S. Novel oral specific drug delivery systems for pharmacotherapy of peptide and nonpeptide drugs. Drugs Today 35 (1999) 537-580
77. Chourasia M.K., and Jain S.K. Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Sci 6 (2003) 33-66